stockrowResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
Follow RMD
Alert me
ResMed Inc. (RMD) Net income
ResMed Inc.'s net income for fiscal 2026 was $1.5B, up 8.75% from $1.4B in fiscal 2025. Over the twelve months to 30 September 2026 it was $1.6B. Over the past ten years it has ranged from $315.6M (fiscal 2018) to $1.5B (fiscal 2026) — the current reading is the highest in ten years. Net income has risen for 5 consecutive fiscal years. ResMed Inc. ranks 3rd of 51 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | $1.5B | 8.75% |
| FY2025 | $1.4B | 37.20% |
| FY2024 | $1.0B | 13.75% |
| FY2023 | $897.6M | 15.15% |
| FY2022 | $779.4M | 64.26% |
| FY2021 | $474.5M | (23.67%) |
| FY2020 | $621.7M | 53.65% |
| FY2019 | $404.6M | 28.20% |
| FY2018 | $315.6M | (7.80%) |
| FY2017 | $342.3M | (2.87%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $418.4M | 9.12% |
| Jun 2026 | $383.4M | (3.84%) |
| Mar 2026 | $398.7M | 1.56% |
| Dec 2025 | $392.6M | 12.64% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| MDLN Medline Inc. compare | $1.9B |
| RMD ResMed Inc. | $1.6B |
| BDX Becton, Dickinson and Company compare | $942.0M |
| ALC Alcon compare | $643.0M |
| WST West Pharmaceutical Services, Inc. compare | $638.9M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| ALGN Align Technology, Inc. compare | $413.6M |
| SOLV Solventum Corporation compare | $156.0M |
| BAX Baxter International Inc. compare | −$723.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RMD
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement